Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06072911
Other study ID # HREBA.CC-23-0207
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 27, 2024
Est. completion date June 30, 2026

Study information

Verified date January 2024
Source University of Alberta
Contact Margaret L McNeely
Phone 780-492-6007
Email mmcneely@ualberta.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Continence, Sexual and Metabolic Health (CONTROL 4 LIFE) study will evaluate the recovery of continence, sexual function, and health outcomes in individuals who have undergone surgery for prostate cancer. The purpose of this study is to better understand the timelines of recovery for these outcomes after surgery for prostate cancer. As part of this study, all participants will receive resources offered by Alberta Health Services regarding pre- and post-prostatectomy care, including information on pelvic floor exercises. Through the CONTROL 4 LIFE study, the investigators will also be evaluating outcomes related to physical activity, fitness and quality of life. These assessments will enable the investigators to better understand how well and how long it takes for individuals to recover after surgery for prostate cancer.


Description:

The investigators aim to conduct a trial examining the feasibility and the effects of a combined pelvic health rehabilitation and exercise program that can be delivered both in-person and virtually in individuals who have been treated with prostatectomy for prostate cancer. This hybrid format will support equitable program delivery regardless of location of residence. To address issues faced by men with prostate cancer, the investigators propose an intervention (offered virtually and in-person) that includes: 1) online education to support continence, sexual and overall health; 2) a group exercise fitness program that considers the needs and restrictions specific to the early post-prostatectomy surgical period, and 3) functional and intensive pelvic floor muscle exercise retraining to promote continence and sexual recovery. Main objectives of this study 1. Determine the feasibility, defined as the acceptability and appropriateness, of a combined pelvic health rehabilitation and exercise fitness program that can be delivered both in-person and virtually. 2. Determine the effects of the program on the primary outcome measure of urinary continence in comparison with usual care. Secondary objectives of this study 1. To determine the effects of the program on cardiometabolic indicators in comparison with usual care. 2. To determine the effects of the program on general fitness, secondary outcomes of urinary continence, sexual function, self-efficacy, and cancer symptom burden, in comparison with usual care.


Recruitment information / eligibility

Status Recruiting
Enrollment 106
Est. completion date June 30, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - have a diagnosis of prostate cancer (stage I to IV); - be scheduled for a prostatectomy surgery (any surgical approach); - have no restriction to participate in at least mild levels of physical activity, as confirmed by the Physical Activity Readiness Questionnaire (PAR-Q+); - speak and understand English. - adult: 18 years of age or older - optional exercise component: willing and able to commit to the 12-week intervention Exclusion Criteria: - have any medical conditions that may interfere with continence (i.e. neurological diseases); - have any contraindications to exercise testing or training; - have recent (>6 months) modifications to any medication aiming to reduce urinary incontinence (i.e. Myrbetric); - do not have regular access to the internet and a smart device or a computer at home/ at their community center; - are already receiving a pelvic floor exercise program through a pelvic floor physical therapist from their community.

Study Design


Intervention

Behavioral:
Pelvic floor exercise program
General exercises will be prescribed along with a specialized pelvic floor program
General exercise
A general progressive resistance exercise program
Physical Activity Counseling
Advice on increasing physical activity

Locations

Country Name City State
Canada University of Alberta Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Completion Rate The number of participants completing the study including all planned outcomes Final assessment at one year
Secondary Recruitment rate Percentage of participants who are eligible and agree to participate One year
Secondary Adherence rate Adherence to the intervention components Post-intervention: 12 weeks
Secondary 24-hour pad test Mean: Individual's urine loss by measuring weight (grams) of an absorbent pad 24 hours at two time points: immediate post surgery and 12 weeks
Secondary Expanded Prostate Cancer Index Composite for Clinical Practice 16-questions: urinary function, sexual and erectile function, bowel and hormonal function; Scores: 0 (no symptoms) to 60 (most severe symptoms); Higher scores indicate worse functioning One-year
Secondary International Consultation on Incontinence Questionnaire 13 questions: occurrence and bother of lower urinary tract symptoms, quality of life; Range of scores: 0-20 voiding subscale; 0-20 incontinence symptoms; Higher scores indicate worse functioning One-year
Secondary 36-Item Short Form Survey Quality of life measure: Items are scored 0-100 (percentage of total possible score): Higher scores equal better quality of life One-year
Secondary Edmonton Symptom Assessment Scale 11-item ordinal scale; Range 0-60; with higher scores indicating higher symptom burden One year
Secondary Self-efficacy Questionnaire: Incontinence 6 item ordinal scale: Range 0-60; Higher scores indicating higher self-efficacy One year
Secondary Grip Strength Dyanometer: mean in kgs 12 weeks
Secondary Lower body strength Sit-to-stand: mean number completed in 30 seconds 12-weeks
Secondary Upper limb mobility Shoulder Range of Motion: mean value in degrees 12 weeks
Secondary Flexibility Sit and reach: mean value in cm 12-weeks
Secondary Balance One-leg stance test: mean time in seconds 12-weeks
Secondary Walking endurance Six-minute walk test: mean distance in metres 12-weeks
Secondary Body Mass Index Height and weight will be combined to calculate BMI: mean: weight in kilograms divided by height in metres squared 12-weeks
Secondary Glucose mmol/L (mean value) 12-weeks
Secondary Insulin level mmol/L (mean value) 12-weeks
Secondary Lipid profile Cholesterol level: mg/dL (mean value) 12-weeks
Secondary Hemoglobin A1c Value in percentage (mean value) 12-weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A